Hims & Hers Health stock (HIMS) trades near $37.36 as of July 1, 2026, after surging roughly 67% in the second quarter of 2026. The 13-analyst average price target sits at $28.35–$30.14, roughly 20% below the current market price. The bull case is Canaccord Genuity's $40 target, raised from $32 in July 2026; the bear case is the street low at $21, implying a 44% downside. The stock's quarterly gain tracked a sequence of operating catalysts: generic semaglutide launched in Canada in late May, the Eucalyptus acquisition closed in early June, and monthly sales growth accelerated from mid-single digits in April to high-teens by June. The FDA's Peptide Compounding Advisory Committee meets July 23–24, 2026, with the agency formally recommending against permitting compounding of certain peptides—a regulatory event that frames the near-term risk for telehealth weight-loss channels.
HIMS Stock Reprices on Operating Catalysts and Business Model Shift
The 67% second-quarter move tracked a sequence of operating catalysts. In late May, Hims launched generic semaglutide in Canada—first-mover access to the weight-loss molecule in a market where the patent picture allows it. In early June, the company closed its acquisition of Eucalyptus, the Australian digital-health group, extending the platform internationally. Through the same stretch, monthly sales growth accelerated from mid-single digits in April to high-teens by June, per the channel work behind BofA's upgrade.
The pivot matters because of what it replaces. Hims built its weight-loss business on compounded semaglutide sold at a fraction of branded prices, a model that put it in open conflict with Novo Nordisk and squarely in the FDA's sights. The new model is distribution partnership: selling branded and authorised products through the same subscriber funnel—more durable, lower margin, and less legally contentious.
"The company's transition away from compounded weight loss drugs toward branded alternatives is gaining traction," said Maria Ripps, Analyst at Canaccord Genuity, who also flagged that a Novo Nordisk executive recently described Hims as one of the pharmaceutical giant's most "voluminous" telehealth partners.
Analyst and Industry Response to HIMS Transition
The most consequential response is Novo Nordisk's. A year after publicly severing its collaboration over compounding, the Danish drugmaker's executives now talk about Hims as a top-volume telehealth channel. Eli Lilly's direct-to-consumer LillyDirect remains the structural counterweight: the bear reading of pharma's posture is that manufacturers tolerate telehealth intermediaries only until their own channels scale.
Wall Street's response is split. Of the 13 covering analysts, the overwhelming majority sit at Hold, and the consensus target of $28–$30 implies double-digit downside—yet the two most recent target changes were both upgrades of 25% or more. BofA Securities raised its target from $25 to $36 but kept a Neutral rating (Allen Lutz). Canaccord Genuity raised its target from $32 to $40 with a Buy rating (Maria Ripps) in July 2026.
Retail investor commentary frames the company as healthcare's platform consolidator. "Hims & Hers has an opportunity to be the aggregator in healthcare, serving tens of millions of customers," argued Travis Hoium, investor and host at Asymmetric Investing, in a July analysis of his largest holding. The counter-signal also lives in public forums: customer complaints about subscription billing practices—sign-up charges without provider contact—recur across community threads.
Price Target Breakdown: $40 Bull Case vs $21 Bear Case
| Scenario | Target | vs $37.36 price | Anchor |
| --- | --- | --- | --- |
| Bull case | $40 | +7% | Canaccord (Ripps, Buy) — branded transition + Novo volume |
| BofA case | $36 | −4% | Raised from $25, Neutral — growth acknowledged, valuation full |
| Street average | $28.35–$30.14 | −20% to −24% | 13 analysts, majority Hold |
| Bear case | $21 | −44% | Street low — FDA compounding risk + churn + competition |
Sources: Benzinga (July 1, 2026); TipRanks and Stock Analysis consensus data (July 10, 2026).
The bull case of $40 is just 7% above the July 1 price, while the bear case of $21 is a 44% fall. That is an asymmetric risk profile: the upside to the most optimistic published target is smaller than the downside to the consensus, let alone the low. For the bulls to be right at these prices, the street's August model refresh—Q2 earnings land early in the month—has to blow through $40, which is precisely what an April-to-June acceleration from mid-single to high-teens growth would justify if it holds.
The technical picture has held through mid-July—the stock's June breakout from the mid-$30s has held on every pullback, per trader commentary across retail forums. HIMS is a consumer-subscription business walking into a binary regulatory date, not a datacentre with contracted backlog.
FDA Peptide Compounding Advisory Committee Review on July 23–24
Hims's compounded-semaglutide business was born in the branded shortage era: when the FDA listed semaglutide as in shortage, compounding pharmacies could legally produce versions, and Hims scaled the cheapest large-scale channel for them. When the agency declared the shortage resolved in early 2025, that legal foundation dissolved—the wind-down that followed cost the company its first Novo Nordisk collaboration and defined the stock's 2025 drawdown.
The FDA's Peptide Compounding Advisory Committee takes up seven peptides on July 23–24, 2026, with the agency having formally recommended against permitting compounding pharmacies to manufacture certain of them. For Hims, the direct revenue exposure is the compounding tail the company has spent a year shrinking—but the second-order exposure is narrative. A hostile committee outcome re-attaches the "regulatory target" discount the branded pivot was meant to remove; a benign one validates the de-risking. Every month of branded mix shift makes the FDA's compounding posture matter less to revenue and more to sentiment alone.
Three Post-FDA Scenarios for HIMS Stock
Scenario one—the acceleration is real (bull, roughly Canaccord's $40 and beyond). If Q2 earnings in early August confirm high-teens exit growth with the branded mix expanding, the street's $28–$30 average is unpayable and targets migrate towards $40-plus.
Scenario two—the FDA reframes the story (bear, towards $21). A sharply negative PCAC outcome on July 23–24, or any signal that regulators view telehealth GLP-1 channels as the next enforcement frontier, restores the 2025 discount. The stock's 67% quarter offers a large profit-taking cushion, and a Hold-heavy street will not defend a valuation its own averages call 20% too high.
Scenario three—the grind (base). A muddled committee outcome and in-line earnings leave HIMS oscillating between the BofA $36 and the consensus $30—a stock that has to keep proving acceleration every 90 days because its price already assumes it. The July 23–24 committee is the near-term coin flip and August earnings the settlement date.
FAQ
What is the bull case for HIMS stock?
$40—Canaccord Genuity's target, raised from $32 in July 2026, resting on the branded weight-loss transition, Novo Nordisk calling Hims one of its most "voluminous" telehealth partners, and sales growth accelerating from mid-single digits in April to high-teens by June.
What is the bear case for HIMS stock?
$21, the lowest Wall Street target—roughly 44% below the July price. It rests on FDA compounding risk (PCAC review July 23–24), a Hold-majority street whose $28–$30 average target is already below the market price, subscription-churn complaints, and Eli Lilly's direct-to-consumer competition.
Why did HIMS stock go up 67% in Q2 2026?
A run of operating catalysts: generic semaglutide launched in Canada in late May, the Eucalyptus acquisition closed in early June, monthly sales growth accelerated through the quarter, and analysts began raising targets—Canaccord to $40 and BofA Securities from $25 to $36.
